Sadaf Rassouli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sadaf Rassouli has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Zahra Hamidi Madani
Department of Obstetrics and Gynecology, Reproductive Health Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
4 shared publications - Zeinab Zamanpour
Department of Gynecology and Obstetrics, School of Medicine, Jundishapur University of Medical Sciences, Ahvaz, Iran
4 shared publications - Maryam Kazemi
Department of Obstetrics and Gynecology, Imam Hossein Hospital, Faculty of Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran
3 shared publications - Moloud Alsadat Mousavi
Department of Gynecology and Obstetrics, Imam Hossein Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Saba Bazzazi
Preventative Gynecology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Sina Salem Ahim
General Medicine, Fasa University of Medical Sciences, Fasa, Iran
2 shared publications
Latest Publications
- Open Access
- 10 March 2026
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 15 (2) , e27691
Antiphospholipid antibody nephropathy in pregnancy; consequences for fetal renal development and maternal health outcomes
Antiphospholipid antibody (aPL) nephropathy in pregnancy is a critical and complex medical condition that poses significant risks to both maternal renal health and fetal development. This autoimmune disorder is characterized by the presence of aPLs, which target phospholipid-binding proteins, leading to a procoagulant state. In the context of pregnancy, this predisposition to thrombosis can manifest as thrombotic microangiopathy (TMA) within the renal vasculature, directly impacting kidney function. The resulting renal microvascular injury contributes to a decline in maternal renal health, potentially leading to proteinuria, hypertension, and even acute kidney injury, exacerbating the already delicate physiological changes of pregnancy. The intricate interplay between autoimmune-mediated thrombosis and placental dysfunction is central to the high-risk nature of this condition. aPLs can cause thrombosis in the placental vasculature, leading to placental insufficiency, intrauterine growth restriction, preeclampsia, and recurrent pregnancy loss. This compromise in placental blood flow not only jeopardizes fetal development but also indirectly strains maternal renal function. The systemic inflammation and endothelial dysfunction associated with aPLs further complicate the clinical picture, making accurate diagnosis and timely intervention paramount for managing these multifaceted challenges. Effective management of aPL nephropathy in pregnancy necessitates a highly individualized and multidisciplinary approach, focusing on meticulous monitoring of both maternal and fetal well-being. This includes close surveillance of renal function, blood pressure, and proteinuria, alongside regular assessments of fetal growth and placental health. Therapeutic strategies often involve anticoagulation with heparin, sometimes combined with low-dose aspirin, to mitigate the thrombotic risk. Such precise monitoring and tailored interventions are crucial for optimizing outcomes, aiming to preserve maternal renal health while supporting successful fetal development in this challenging clinical scenario.
- 10 March 2026
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 15 (2) , e27691
Open AccessAntiphospholipid antibody nephropathy in pregnancy; consequences for fetal renal development and maternal health outcomes
Antiphospholipid antibody (aPL) nephropathy in pregnancy is a critical and complex medical condition that poses significant risks to both maternal renal health and fetal development. This autoimmune disorder is characterized by the presence of aPLs, which target phospholipid-binding proteins, leading to a procoagulant state. In the context of pregnancy, this predisposition to thrombosis can manifest as thrombotic microangiopathy (TMA) within the renal vasculature, directly impacting kidney function. The resulting renal microvascular injury contributes to a decline in maternal renal health, potentially leading to proteinuria, hypertension, and even acute kidney injury, exacerbating the already delicate physiological changes of pregnancy. The intricate interplay between autoimmune-mediated thrombosis and placental dysfunction is central to the high-risk nature of this condition. aPLs can cause thrombosis in the placental vasculature, leading to placental insufficiency, intrauterine growth restriction, preeclampsia, and recurrent pregnancy loss. This compromise in placental blood flow not only jeopardizes fetal development but also indirectly strains maternal renal function. The systemic inflammation and endothelial dysfunction associated with aPLs further complicate the clinical picture, making accurate diagnosis and timely intervention paramount for managing these multifaceted challenges. Effective management of aPL nephropathy in pregnancy necessitates a highly individualized and multidisciplinary approach, focusing on meticulous monitoring of both maternal and fetal well-being. This includes close surveillance of renal function, blood pressure, and proteinuria, alongside regular assessments of fetal growth and placental health. Therapeutic strategies often involve anticoagulation with heparin, sometimes combined with low-dose aspirin, to mitigate the thrombotic risk. Such precise monitoring and tailored interventions are crucial for optimizing outcomes, aiming to preserve maternal renal health while supporting successful fetal development in this challenging clinical scenario.
- Open Access
- 26 January 2026
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 11 (2) , e39328
Role of uterine artery Doppler sonography in prediction and management of preeclampsia: a systematic review analysis of the recent 10-year evidence
Introduction: Preeclampsia (PE) is a leading cause of maternal and perinatal morbidity worldwide, and early identification of at-risk pregnancies remains a clinical priority. This systematic review synthesizes evidence from the past decade to evaluate the diagnostic performance and clinical utility of uterine artery Doppler (UAD) sonography in predicting and guiding management of PE. Materials and Methods: We systematically searched PubMed, Embase, Scopus, Web of Science, Cochrane Library, and Google Scholar for English-language original studies published between 2016 and 2025 that evaluated UAD parameters for predicting PE. Two reviewers independently extracted data on study design, gestational timing, Doppler findings, and diagnostic accuracy using a standardized form. Results: In this review of 18 observational and cohort studies published over the past decade, UAD sonography demonstrated moderate to high diagnostic accuracy for predicting PE, with parameters such as pulsatility index (PI), resistive index (RI), and the presence of a diastolic notch, alone or in combination, yielding sensitivities ranging from ~60% to 91% and specificities up to 99%. First-trimester assessments showed particular promise, especially when Doppler indices were combined with biochemical markers, and second-trimester measurements maintained predictive value for both early- and late-onset disease. Conclusion: These findings pose UAD sonography as a noninvasive, cost-effective tool for early risk stratification of PE and support its incorporation into routine antenatal screening. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251173030 and the Research Registry (UIN: reviewregistry2054) websites.
- 26 January 2026
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 11 (2) , e39328
Open AccessRole of uterine artery Doppler sonography in prediction and management of preeclampsia: a systematic review analysis of the recent 10-year evidence
Introduction: Preeclampsia (PE) is a leading cause of maternal and perinatal morbidity worldwide, and early identification of at-risk pregnancies remains a clinical priority. This systematic review synthesizes evidence from the past decade to evaluate the diagnostic performance and clinical utility of uterine artery Doppler (UAD) sonography in predicting and guiding management of PE. Materials and Methods: We systematically searched PubMed, Embase, Scopus, Web of Science, Cochrane Library, and Google Scholar for English-language original studies published between 2016 and 2025 that evaluated UAD parameters for predicting PE. Two reviewers independently extracted data on study design, gestational timing, Doppler findings, and diagnostic accuracy using a standardized form. Results: In this review of 18 observational and cohort studies published over the past decade, UAD sonography demonstrated moderate to high diagnostic accuracy for predicting PE, with parameters such as pulsatility index (PI), resistive index (RI), and the presence of a diastolic notch, alone or in combination, yielding sensitivities ranging from ~60% to 91% and specificities up to 99%. First-trimester assessments showed particular promise, especially when Doppler indices were combined with biochemical markers, and second-trimester measurements maintained predictive value for both early- and late-onset disease. Conclusion: These findings pose UAD sonography as a noninvasive, cost-effective tool for early risk stratification of PE and support its incorporation into routine antenatal screening. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251173030 and the Research Registry (UIN: reviewregistry2054) websites.
- Open Access
- 7 December 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 15 (1) , e12823
Placenta, platelets, and podocytes; the triad of renal injury in pregnant women with antiphospholipid syndrome
The intricate triad of placenta, platelets, and podocytes represents a central framework for understanding the multifactorial renal injury associated with antiphospholipid syndrome (APS) during pregnancy. This triadic interaction underscores a pathophysiological continuum driven by thrombosis, inflammation, and endothelial dysfunction that disrupts both placental and renal homeostasis. In pregnant women with APS, the placenta functions as a key initiator of systemic disturbances through procoagulant and proinflammatory mediators that alter vascular tone and promote immune activation. These placental signals propagate into the maternal circulation, stimulating platelet activation and aggregation that intensify microvascular thrombotic damage. Activated platelets further contribute to endothelial injury by releasing cytokines, chemokines, and growth factors that perpetuate inflammatory cascades and coagulative imbalance. At the renal glomerular level, podocytes serve as critical yet vulnerable responders within this network. They experience direct insults from circulating antiphospholipid antibodies and secondary injury from ischemic and hemodynamic stress induced by microthrombi and endothelial derangement. The consequent podocyte depletion and barrier disruption lead to proteinuria and progressive glomerular dysfunction characteristic of APS nephropathy. This integrative model highlights how maternal, hematologic, and renal compartments intersect in a self-reinforcing cycle of injury, illuminating potential therapeutic targets that modulate platelet activation, placental inflammation, and podocyte resilience.
- 7 December 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 15 (1) , e12823
Open AccessPlacenta, platelets, and podocytes; the triad of renal injury in pregnant women with antiphospholipid syndrome
The intricate triad of placenta, platelets, and podocytes represents a central framework for understanding the multifactorial renal injury associated with antiphospholipid syndrome (APS) during pregnancy. This triadic interaction underscores a pathophysiological continuum driven by thrombosis, inflammation, and endothelial dysfunction that disrupts both placental and renal homeostasis. In pregnant women with APS, the placenta functions as a key initiator of systemic disturbances through procoagulant and proinflammatory mediators that alter vascular tone and promote immune activation. These placental signals propagate into the maternal circulation, stimulating platelet activation and aggregation that intensify microvascular thrombotic damage. Activated platelets further contribute to endothelial injury by releasing cytokines, chemokines, and growth factors that perpetuate inflammatory cascades and coagulative imbalance. At the renal glomerular level, podocytes serve as critical yet vulnerable responders within this network. They experience direct insults from circulating antiphospholipid antibodies and secondary injury from ischemic and hemodynamic stress induced by microthrombi and endothelial derangement. The consequent podocyte depletion and barrier disruption lead to proteinuria and progressive glomerular dysfunction characteristic of APS nephropathy. This integrative model highlights how maternal, hematologic, and renal compartments intersect in a self-reinforcing cycle of injury, illuminating potential therapeutic targets that modulate platelet activation, placental inflammation, and podocyte resilience.
- 12 October 2025
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 11 (1) , e39282
Investigating the relationship between vitamin B intake and endometriosis: a systematic review and meta-analysis
Introduction: Vitamin B promotes the inactive metabolism of estrogen and inhibits endometrial growth. Accordingly, the present study aimed to examine the relationship between vitamin B intake and endometriosis. Materials and Methods: Databases Scopus, PubMed, ProQuest, Web of Science, Cochrane, Embase, and Google Scholar Search Engine were used for articles published until July 18, 2025. Data was entered into SPSS 19 and analyzed using STATA 14. Results: Generally, administration of vitamins B2 (OR: 0.76, 95% CI: 0.64, 0.90) and B3 (OR: 0.98, 95% CI: 0.96, 1) reduced the risk of endometriosis. However, the relationship between vitamins B1 (OR: 1.04, 95% CI: 0.92, 1.17), B6 (OR: 0.98, 95% CI: 0.89, 1.08), B9 (OR: 1.01, 95% CI: 0.84, 1.21), and B12 (OR: 1.06, 95% CI: 0.98, 1.14) and endometriosis was statistically insignificant. According to the subgroup analysis, vitamin B1 intake in cohort studies increased the risk of endometriosis. Vitamin B2 administration in case-control studies and in the fourth quartile reduced the risk of endometriosis. Vitamin B9 intake, on the other hand, increased the risk of endometriosis in cohort studies and the fourth quartile. Conclusion: Vitamin B2 and B3 intake reduced the risk of endometriosis in women by up to 24% and 2%, respectively. However, to ensure the validity of the results, further studies on this subject are required. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251112519) and Research Registry (UIN: reviewregistry2028) websites.
- 12 October 2025
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 11 (1) , e39282
Investigating the relationship between vitamin B intake and endometriosis: a systematic review and meta-analysis
Introduction: Vitamin B promotes the inactive metabolism of estrogen and inhibits endometrial growth. Accordingly, the present study aimed to examine the relationship between vitamin B intake and endometriosis. Materials and Methods: Databases Scopus, PubMed, ProQuest, Web of Science, Cochrane, Embase, and Google Scholar Search Engine were used for articles published until July 18, 2025. Data was entered into SPSS 19 and analyzed using STATA 14. Results: Generally, administration of vitamins B2 (OR: 0.76, 95% CI: 0.64, 0.90) and B3 (OR: 0.98, 95% CI: 0.96, 1) reduced the risk of endometriosis. However, the relationship between vitamins B1 (OR: 1.04, 95% CI: 0.92, 1.17), B6 (OR: 0.98, 95% CI: 0.89, 1.08), B9 (OR: 1.01, 95% CI: 0.84, 1.21), and B12 (OR: 1.06, 95% CI: 0.98, 1.14) and endometriosis was statistically insignificant. According to the subgroup analysis, vitamin B1 intake in cohort studies increased the risk of endometriosis. Vitamin B2 administration in case-control studies and in the fourth quartile reduced the risk of endometriosis. Vitamin B9 intake, on the other hand, increased the risk of endometriosis in cohort studies and the fourth quartile. Conclusion: Vitamin B2 and B3 intake reduced the risk of endometriosis in women by up to 24% and 2%, respectively. However, to ensure the validity of the results, further studies on this subject are required. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251112519) and Research Registry (UIN: reviewregistry2028) websites.
- Open Access
- 25 November 2024
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 11 (2) , e41724
Association between metabolic syndrome and risk of endometrial cancer; a systematic review and meta-analysis
Introduction: Endometrial cancer is one of the most prevalent female malignancies, with various factors, including metabolic syndrome, contributing to its incidence. Thus, this study aims to evaluate the association between metabolic syndrome and the risk of endometrial carcinoma. Materials and Methods: In this systematic review and meta-analysis, two independent authors searched electronic databases, including Cochrane, PubMed, ProQuest, Web of Science, and the Google Scholar search engine up to May 16, 2024. Data analysis was conducted using STATA 14 software with a significance level of P < 0.05 for all tests. Results: A pooled analysis of 12 observational studies found that metabolic syndrome elevated the risk of endometrial carcinoma by 37% overall (OR: 1.37, 95% CI: 1.33, 1.42), 35% in cohort studies (OR: 1.35, 95% CI: 1.29, 1.42), and 40% in case-control studies (OR: 1.40, 95% CI: 1.33, 1.48). However, hypertension increased the risk of endometrial carcinoma by 25% (OR: 1.25, 95% CI: 1.18, 1.33), fasting hyperglycemia by 25% (OR: 1.25, 95% CI: 1.15, 1.37), hypertriglyceridemia by 17% (OR: 1.17, 95% CI: 1.13, 1.21), low high density lipoprotein (HDL) by 20% (OR:1.20, 95% CI: 1.12, 1.28), increased waist circumference by 59% (OR:1.59, 95% CI: 1.43, 1.77), pre-menopausal period by 67% (OR:1.67, 95% CI: 1.38, 2.02), and post-menopausal period by 61% (OR: 1.61, 95% CI: 1.17, 2.21). Likewise, obesity almost doubled the risk of endometrial carcinoma (OR: 2.13, 95% CI: 1.65, 2.75). Conclusion: Metabolic syndrome increases the risk of endometrial carcinoma, with obesity being the most dangerous risk factor for endometrial cancer. Thus, managing metabolic disorders in women can be an important step toward reducing the incidence of endometrial cancer. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024551509) and Research Registry (UIN: reviewregistry1838).
- 25 November 2024
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 11 (2) , e41724
Open AccessAssociation between metabolic syndrome and risk of endometrial cancer; a systematic review and meta-analysis
Introduction: Endometrial cancer is one of the most prevalent female malignancies, with various factors, including metabolic syndrome, contributing to its incidence. Thus, this study aims to evaluate the association between metabolic syndrome and the risk of endometrial carcinoma. Materials and Methods: In this systematic review and meta-analysis, two independent authors searched electronic databases, including Cochrane, PubMed, ProQuest, Web of Science, and the Google Scholar search engine up to May 16, 2024. Data analysis was conducted using STATA 14 software with a significance level of P < 0.05 for all tests. Results: A pooled analysis of 12 observational studies found that metabolic syndrome elevated the risk of endometrial carcinoma by 37% overall (OR: 1.37, 95% CI: 1.33, 1.42), 35% in cohort studies (OR: 1.35, 95% CI: 1.29, 1.42), and 40% in case-control studies (OR: 1.40, 95% CI: 1.33, 1.48). However, hypertension increased the risk of endometrial carcinoma by 25% (OR: 1.25, 95% CI: 1.18, 1.33), fasting hyperglycemia by 25% (OR: 1.25, 95% CI: 1.15, 1.37), hypertriglyceridemia by 17% (OR: 1.17, 95% CI: 1.13, 1.21), low high density lipoprotein (HDL) by 20% (OR:1.20, 95% CI: 1.12, 1.28), increased waist circumference by 59% (OR:1.59, 95% CI: 1.43, 1.77), pre-menopausal period by 67% (OR:1.67, 95% CI: 1.38, 2.02), and post-menopausal period by 61% (OR: 1.61, 95% CI: 1.17, 2.21). Likewise, obesity almost doubled the risk of endometrial carcinoma (OR: 2.13, 95% CI: 1.65, 2.75). Conclusion: Metabolic syndrome increases the risk of endometrial carcinoma, with obesity being the most dangerous risk factor for endometrial cancer. Thus, managing metabolic disorders in women can be an important step toward reducing the incidence of endometrial cancer. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024551509) and Research Registry (UIN: reviewregistry1838).
- Open Access
- 22 August 2023
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 11 (1) , e40572
Impact of analgesics on the risk of ovarian cancer; a systematic review and meta-analysis of cohort and case-control studies
Introduction: Ovarian cancer is the sixth leading cancer-related mortality cause in women worldwide. Analgesics may hinder the occurrence of ovarian cancer through inflammation relief. The present study seeks to examine the relationship between analgesic consumption and ovarian cancer risk through a systematic review and meta-analysis. Materials and Methods: PubMed, Scopus, Web of Science, Cochrane databases, and Google Scholar search engines were searched for works published by May 2023 using standard keywords to collect the required data sources. Acquired data were then analyzed in STATA version14, considering a significance level of P < 0.05 in statistical tests. Results: The present meta-analysis comprised 21 studies (14 case-control and 7 cohort studies) performed on 53,755 subjects. Results indicated that taking aspirin reduced the risk of ovarian cancer by 8% (OR: 0.92; 95% CI: 0.87, 0.98), whereas other non-aspirin NSAIDs (non-steroidal anti-inflammatory drugs) did not significantly affect the ovarian cancer risk (OR: 0.91; 95% CI: 0.81, 1.02). Similar results were observed in the case of ibuprofen and acetaminophen, with non-significant relationships between the risk of ovarian cancer and with the consumption of both acetaminophen (OR: 0.95; 95% CI: 0.84, 1.08) and ibuprofen (OR: 0.76; 95% CI: 0.50, 1.14). Furthermore, the duration of analgesic consumption was not significantly linked to the risk of ovarian cancer in the case of all studied drugs. Conclusion: Among aspirin, ibuprofen, acetaminophen, and non-aspirin NSAIDs, only aspirin was found to reduce the risk of ovarian cancer in women while the other studied drugs did not influence the studied risk. However, further research is recommended to confirm the results. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023434730) and Research Registry (UIN: reviewregistry1668) websites.
- 22 August 2023
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 11 (1) , e40572
Open AccessImpact of analgesics on the risk of ovarian cancer; a systematic review and meta-analysis of cohort and case-control studies
Introduction: Ovarian cancer is the sixth leading cancer-related mortality cause in women worldwide. Analgesics may hinder the occurrence of ovarian cancer through inflammation relief. The present study seeks to examine the relationship between analgesic consumption and ovarian cancer risk through a systematic review and meta-analysis. Materials and Methods: PubMed, Scopus, Web of Science, Cochrane databases, and Google Scholar search engines were searched for works published by May 2023 using standard keywords to collect the required data sources. Acquired data were then analyzed in STATA version14, considering a significance level of P < 0.05 in statistical tests. Results: The present meta-analysis comprised 21 studies (14 case-control and 7 cohort studies) performed on 53,755 subjects. Results indicated that taking aspirin reduced the risk of ovarian cancer by 8% (OR: 0.92; 95% CI: 0.87, 0.98), whereas other non-aspirin NSAIDs (non-steroidal anti-inflammatory drugs) did not significantly affect the ovarian cancer risk (OR: 0.91; 95% CI: 0.81, 1.02). Similar results were observed in the case of ibuprofen and acetaminophen, with non-significant relationships between the risk of ovarian cancer and with the consumption of both acetaminophen (OR: 0.95; 95% CI: 0.84, 1.08) and ibuprofen (OR: 0.76; 95% CI: 0.50, 1.14). Furthermore, the duration of analgesic consumption was not significantly linked to the risk of ovarian cancer in the case of all studied drugs. Conclusion: Among aspirin, ibuprofen, acetaminophen, and non-aspirin NSAIDs, only aspirin was found to reduce the risk of ovarian cancer in women while the other studied drugs did not influence the studied risk. However, further research is recommended to confirm the results. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023434730) and Research Registry (UIN: reviewregistry1668) websites.